Acne and PCOS are less frequent in women with Mayer-Rokitansky-Küster-Hauser syndrome despite a high rate of hyperandrogenemia: a cross-sectional study

Reproductive Biology and Endocrinology

Sara Y Brucker²  Matthias Möhrle³  Diethelm Wallwiener²  Melanie Henes²  Norbert Schäffeler⁴  Gabriele Conzelmann¹  Katharina Rall² 

[1] Department of Dermatology, Tübingen University Hospital, Liebermeisterstrasse 25, 72076 Tübingen, Germany;Department of Obstetrics and Gynecology, Tübingen University Hospital, Calwerstrasse 7, 72076 Tübingen, Germany;Praxisklinik Tübingen Haut und Venen, Europaplatz 2, 72072 Tübingen, Germany;Division of Psychosomatic Medicine and Psychotherapy, Department of Internal Medicine VI, Tübingen University Hospital, Osianderstrasse 5, 72076 Tübingen, Germany

关键词: PCOS;    WNT4;    Hyperandrogenemia;    Dermatology life quality index (DLQI);    Quality of life;    Acne;    MRKH;   

Others  :  804503
DOI  :  10.1186/1477-7827-12-23

 received in 2014-01-09, accepted in 2014-03-06,  发布年份 2014

【 摘 要 】

Background

Acne is a very common skin condition during adolescence and adulthood. Patients with uterovaginal agenesis (Mayer-Rokitansky-Küster-Hauser syndrome, MRKH) treated at the Tübingen University Center for Rare Female Genital Malformations, however, clinically appeared to be less frequently affected by acne. The etiology of MRKH syndrome remains unknown. The only known MRKH-associated mutations are located within the WNT4 gene and lead to an atypical form of MRKH syndrome associated with clinical and biochemical hyperandrogenism. Our study aimed to assess the frequency, severity, and self-evaluation of acne in MRKH patients and to correlate the clinical findings with hormone analyses.

Methods

As part of a cross-sectional longterm follow-up study after laparoscopic assisted creation of a neovagina a questionnaire was sent to 149 MRKH patients aged 16–44 years comprising 26 items concerning prevalence and self-evaluation of acne, and the effects of acne on quality of life. The questionnaire was derived from one used in a former epidemiological study of acne in 4,000 women. Blood for hormone analyses was collected routinely during the clinical visit.

Results

Fully completed, evaluable questionnaires were returned by 69/149 (46%) women. Of these respondents, 42 (60.1%) showed hyperandrogenemia without other clinical signs of virilization but only 17 (24.6%) reported acne (8 (11.6%) had physiological acne and 9 (13.0%) clinical acne) and only 10 (14.5%) reported receiving medical treatment for their acne. Effects of acne on quality of life were minor. Only 4 patients (5.8%) with PCOS were identified, among them one with physiological acne, the other three within the acne-free group.

Conclusions

Although hyperandrogenemia is common, acne is significantly less frequent in women with MRKH than reported in the literature for non-MRKH women, and is seldom treated medically. Patients in this study appeared resistant to acne to some extent, possibly due to the sebaceous glands in the acne regions being less sensitive to androgens compared to the normal population. A WNT4 mutation is unlikely to be the main cause of MRKH syndrome in our hyperandrogenemic patients.

【 授权许可】

   
2014 Rall et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Committee on Adolescent Health Care: Committee opinion: no. 562: mullerian agenesis: diagnosis, management, and treatment. Obstet Gynecol 2013, 121(5):1134-1137.
• [2]Morcel K, Camborieux L, Guerrier D: Mayer-rokitansky-Kuster-Hauser (MRKH) syndrome. Orphanet J Rare Dis 2007, 2:13. BioMed Central Full Text
• [3]Laufer MR: Congenital absence of the vagina: in search of the perfect solution. When, and by what technique, should a vagina be created? Curr Opin Obstet Gynecol 2002, 14(5):441-444.
• [4]Folch M, Pigem I, Konje JC: Mullerian agenesis: etiology, diagnosis, and management. Obstet Gynecol Surv 2000, 55(10):644-649.
• [5]Strissel PL, Oppelt P, Cupisti S, Stiegler E, Beckmann MW, Strick R: Assessment of pituitary and steroid hormones and members of the TGF-beta superfamily for ovarian function in patients with congenital uterus and vaginal aplasia (MRKH syndrome). Horm Metab Res 2009, 41(5):408-413.
• [6]Carranza-Lira S, Forbin K, Martinez-Chequer JC: Rokitansky syndrome and MURCS association–clinical features and basis for diagnosis. Int J Fertil Womens Med 1999, 44(5):250-255.
• [7]Sultan C, Biason-Lauber A, Philibert P: Mayer-rokitansky-Kuster-Hauser syndrome: recent clinical and genetic findings. Gynecol Endocrinol 2009, 25(1):8-11.
• [8]Biason-Lauber A, Konrad D: WNT4 and sex development. Sex Dev 2008, 2(4–5):210-218.
• [9]Philibert P, Biason-Lauber A, Rouzier R, Pienkowski C, Paris F, Konrad D, Schoenle E, Sultan C: Identification and functional analysis of a new WNT4 gene mutation among 28 adolescent girls with primary amenorrhea and mullerian duct abnormalities: a french collaborative study. J Clin Endocrinol Metab 2008, 93(3):895-900.
• [10]Philibert P, Biason-Lauber A, Gueorguieva I, Stuckens C, Pienkowski C, Lebon-Labich B, Paris F, Sultan C: Molecular analysis of WNT4 gene in four adolescent girls with mullerian duct abnormality and hyperandrogenism (atypical Mayer-rokitansky-Kuster-Hauser syndrome). Fertil Steril 2011, 95(8):2683-2686.
• [11]Biason-Lauber A, Konrad D, Navratil F, Schoenle EJ: A WNT4 mutation associated with mullerian-duct regression and virilization in a 46,XX woman. N Engl J Med 2004, 351(8):792-798.
• [12]Biason-Lauber A, De Filippo G, Konrad D, Scarano G, Nazzaro A, Schoenle EJ: WNT4 Deficiency–a clinical phenotype distinct from the classic Mayer-rokitansky-Kuster-Hauser syndrome: a case report. Hum Reprod 2007, 22(1):224-229.
• [13]Brucker SY, Gegusch M, Zubke W, Rall K, Gauwerky JF, Wallwiener D: Neovagina creation in vaginal agenesis: development of a new laparoscopic vecchietti-based procedure and optimized instruments in a prospective comparative interventional study in 101 patients. Fertil Steril 2008, 90(5):1940-1952.
• [14]Ghodsi SZ, Orawa H, Zouboulis CC: Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol 2009, 129(9):2136-2141.
• [15]Law MP, Chuh AA, Lee A, Molinari N: Acne prevalence and beyond: acne disability and its predictive factors among Chinese late adolescents in Hong Kong. Clin Exp Dermatol 2010, 35(1):16-21.
• [16]Poli F, Dreno B, Verschoore M: An epidemiological study of acne in female adults: results of a survey conducted in France. J Eur Acad Dermatol Venereol 2001, 15(6):541-545.
• [17]Goulden V, Stables GI, Cunliffe WJ: Prevalence of facial acne in adults. J Am Acad Dermatol 1999, 41(4):577-580.
• [18]Cunliffe WJ, Gould DJ: Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J 1979, 1(6171):1109-1110.
• [19]Nast A, Dréno B, Bettoli V, Degitz K, Erdmann R, Finlay AY, Ganceviciene R, Haedersdal M, Layton A, López-Estebaranz JL, Ochsendorf F, Oprica C, Rosumeck S, Rzany B, Sammain A, Simonart T, Veien NK, Zivković MV, Zouboulis CC, Gollnick H: European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol 2012, 26(Suppl 1):1-29.
• [20]Archer CB, Cohen SN, Baron SE: Guidance on the diagnosis and clinical management of acne. Clin Exp Dermatol 2012, 37(Suppl 1):1-6.
• [21]Zouboulis CC: Acne vulgaris. Rolle der hormone [acne vulgaris. The role of hormones]. Hautarzt 2010, 61(2):107-108.
• [22]Walton S, Wyatt EH, Cunliffe WJ: Genetic control of sebum excretion and acne–a twin study. Br J Dermatol 1988, 118(3):393-396.
• [23]Goulden V, McGeown CH, Cunliffe WJ: The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals. Br J Dermatol 1999, 141(2):297-300.
• [24]Balen A: The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 2004, 18:685-706.
• [25]Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25.
• [26]Ugur M, Karakaya S, Zorlu G, Arslan S, Gülerman C, Kükner S, Gökmen O: Polycystic ovaries in association with müllerian anomalies. Eur J Obstet Gynecol Reprod Biol 1995, 62:57-59.
• [27]Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19(3):210-216.
• [28]Dermatologischer Lebensqualitäts Fragebogen [http://www.dermatology.org.uk/downloads/DLQI-Germany-German(formatted).pdf webcite]
• [29]Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998, 83(9):3078-3082.
• [30]Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000, 85(7):2434-2438.
• [31]Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR: Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004, 89(2):453-462.
• [32]Huang A, Brennan K, Azziz R: Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril 2010, 93(6):1938-1941.
• [33]Rademaker M, Garioch JJ, Simpson NB: Acne in schoolchildren: no longer a concern for dermatologists. BMJ 1989, 298(6682):1217-1219.
• [34]Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, Elewski BE: The prevalence of acne in adults 20 years and older. J Am Acad Dermatol 2008, 58(1):56-59.
• [35]Jansen T, Grabbe S, Plewig G: Klinische formen der akne [clinical variants of acne]. Hautarzt 2005, 56(11):1018-1026.
• [36]Jemec GB, Linneberg A, Nielsen NH, Frolund L, Madsen F, Jorgensen T: Have oral contraceptives reduced the prevalence of acne? a population-based study of acne vulgaris, tobacco smoking and oral contraceptives. Dermatology 2002, 204(3):179-184.
• [37]Rott H: Hormonal contraception in thrombophilic adolescents: risk of thrombosis and recommendations. Hamostaseologie 2012, 32(1):15-21.
• [38]Wiegratz I, Thaler CJ: Hormonal contraception–what kind, when, and for whom? Dtsch Arztebl Int 2011, 108(28–29):495-505. quiz 506
• [39]Schäfer T, Nienhaus A, Vieluf D, Berger J, Ring J: Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol 2001, 145(1):100-104.
• [40]Firooz A, Sarhangnejad R, Davoudi SM, Nassiri-Kashani M: Acne and smoking: is there a relationship? BMC Dermatol 2005, 5:2. BioMed Central Full Text
• [41]Smoking habits by age-groups (2009) [http://www.destatis.de/EN/FactsFigures/SocietyState/Health/HealthStatusBehaviourRelevantHealth/Tables/SmokingHabits.html webcite]
• [42]Grabmeier B, Landthaler M, Hohenleutner S: Menstruationszyklus und haut [the menstrual cycle and the skin]. J Dtsch Dermatol Ges 2005, 3(1):52-63.
• [43]Stoll S, Shalita AR, Webster GF, Kaplan R, Danesh S, Penstein A: The effect of the menstrual cycle on acne. J Am Acad Dermatol 2001, 45(6):957-960.
• [44]Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY: The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999, 140(4):672-676.
• [45]Lasek RJ, Chren MM: Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998, 134(4):454-458.
• [46]Lehmann HP, Robinson KA, Andrews JS, Holloway V, Goodman SN: Acne therapy: a methodologic review. J Am Acad Dermatol 2002, 47(2):231-240.
• [47]Stathakis V, Kilkenny M, Marks R: Descriptive epidemiology of acne vulgaris in the community. Australas J Dermatol 1997, 38(3):115-123.
• [48]Lucky AW, Barber BL, Girman CJ, Williams J, Ratterman J, Waldstreicher J: A multirater validation study to assess the reliability of acne lesion counting. J Am Acad Dermatol 1996, 35(4):559-565.
• [49]Hayashi N, Akamatsu H, Kawashima M: Establishment of grading criteria for acne severity. J Dermatol 2008, 35(5):255-260.
• [50]Doshi A, Zaheer A, Stiller MJ: A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol 1997, 36(6):416-418.
• [51]Burke BM, Cunliffe WJ: The assessment of acne vulgaris–the Leeds technique. Br J Dermatol 1984, 111(1):83-92.
• [52]Nast A, Bayerl C, Borelli C, Degitz K, Dirschka T, Erdmann R, Fluhr J, Gieler U, Hartwig R, Meigel E-M, Möller S, Ochsendorf F, Podda M, Rabe T, Rzany B, Sammain A, Schink S, Zouboulis CC, Gollnick H, German Society of Dermatology (DDG) and the Association of German Dermatologists (BVDD): S2k-Leitlinie zur therapie der akne [S2k-guideline for therapy of acne]. J Dtsch Dermatol Ges 2010, 8:s1-s59.